… FASTACT-2 is a randomized, placebo-controlled, phase 3 study in first-line advanced
NSCLC, which met its primary endpoint of significantly prolonged PFS with intercalated erlotinib …

… with lung cancer … in phase III study as initial treatment in patients with lung adenocarcinoma
and primary EGFR mutations. Data in mice with L858R and T790M erlotinib-resistant lung …

… The ATLAS trial was a phase III study comparing maintenance erlotinib plus bevacizumab
versus bevacizumab alone in patients with NSCLC without progressive disease after four …

… -naive patients with unresectable stage III or IV NSCLC; age … erlotinib combined with GC
was not significantly inferior to GC alone, with the exception of increased incidences of grade 3…

… Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small
cell lung cancer: the Tarceva Lung Cancer … TRIBUTE: a phase III trial of erlotinib …

… , the previous Phase I study demonstrated adequate absorption of oral high-dose erlotinib, …
The Phase I/II trial reported here was designed to evaluate the tolerability and efficacy of …

… Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic … Because
of this limitation, we undertook this phase 2 trial to examine the combination of erlotinib and …

… cancer [2, 3]. Prospective data in the elderly population derived especially from two Italian
phase III … Europe for the treatment of recurrent NSCLC are erlotinib [9] and, recently, gefitinib (…

… , and head and neck squamous cell cancer, respectively, show favorable activity compared
… Phase III trials with erlotinib in non-small cell lung cancer and pancreatic cancer are in …

… Patients eligible for this study were aged ≥70 years and had confirmed stage III or IV or
postoperative recurrent NSCLC. The patients were previously treated with 1 or 2 chemotherapy …